ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Experimental Pharmacology and Drug Discovery

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1557193

This article is part of the Research TopicInsights in Experimental Pharmacology and Drug Discovery: 2024View all 13 articles

Vitexicarpin demonstrates anticancer potential by inhibiting anoctamin 1 in colorectal and non-small cell lung cancers

Provisionally accepted
Yohan SeoYohan Seo1*Sion LeeSion Lee2Sung Baek JeongSung Baek Jeong2Minuk KimMinuk Kim2Deok Kyu YoonDeok Kyu Yoon2Raju DasRaju Das3Armin SultanaArmin Sultana3Kentu DasKentu Das3Jae-Eon LeeJae-Eon Lee2Yong Hyun JeonYong Hyun Jeon2Thi Thanh Huong PhanThi Thanh Huong Phan4Nguyen Xuan NhiemNguyen Xuan Nhiem4JooHan WooJooHan Woo3Chul Soon ParkChul Soon Park1
  • 1Korea Bio Polytechnic University, Nonsan, South Chungcheong, Republic of Korea
  • 2Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu, Daegu, Republic of Korea
  • 3College of Medicine, Dongguk University, Gyeongju, North Gyeongsang, Republic of Korea
  • 4Vietnam Academy of Science and Technology, Hanoi, Vietnam

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and doselimiting toxicities, which often result in treatment failure. NSCLC, in particular, has a high mortality rate attributed to late-stage diagnosis and therapeutic resistance. Anoctamin 1 (ANO1), a calcium-activated chloride channel, has been implicated in cancer progression and is an emerging therapeutic target. In this study, we identified vitexicarpin, a flavonoid isolated from Vitex trifolia, as a novel ANO1 inhibitor with anticancer potential. Vitexicarpin inhibited ANO1 channel function, reduced ANO1 protein levels, decreased cancer cell viability, and induced apoptosis in CRC and NSCLC cell lines. Importantly, vitexicarpin exhibited minimal hepatotoxicity and negligible hERG channel inhibition, supporting its safety profile. Collectively, our findings suggest that vitexicarpin is a promising candidate for the treatment of CRC and NSCLC through selective inhibition of ANO1.

Keywords: ANO1, Vitexicarpin, colorectal cancer, Non-small cell lung cancer, Apoptosis

Received: 08 Jan 2025; Accepted: 06 May 2025.

Copyright: © 2025 Seo, Lee, Jeong, Kim, Yoon, Das, Sultana, Das, Lee, Jeon, Phan, Nhiem, Woo and Park. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yohan Seo, Korea Bio Polytechnic University, Nonsan, 320-905, South Chungcheong, Republic of Korea

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material